Amgen | A Worldwide Pioneer in Biotechnology

Amgen | A Worldwide Pioneer in Biotechnology

$name
$name

Press Release 02.02.2023

TEZSPIRE® Approved for Self-Administration in the U.S. With a New Pre-Filled Pen
Read Press Release
Arrow
❮1 / 6❯
$name
$name

Press Release 01.31.2023

Amgen Announces 2022 Fourth Quarter and Full Year Financial Results
Read Press Release
Arrow
Listen to Replay
Arrow
❮2 / 6❯
$name
$name

Patients 01.31.2023

One Common Mission to Serve Patients: Amgen Operations Shine with U.S. Biosimilar Launch
Read Story
Arrow
❮3 / 6❯
$name
$name

Press Release 01.31.2023

AMJEVITA™ (adalimumab-atto), First Biosimilar to Humira®, Now Available in the United States
Read Press Release
Arrow
❮4 / 6❯
$name
$name

Patients 01.24.2023

Leaders in Patient Advocacy Share Accomplishments and Aspirations
Read Story
Arrow
❮5 / 6❯
$name
$name

Science & Innovation 01.19.2023

Collaborating to Address Moderate to Severe Atopic Dermatitis

Amgen's clinical trial program investigates a potential first-in-class mechanism of action for moderate to severe atopic dermatitis.
Read Story
Arrow
❮6 / 6❯
$link.Title
SCIENCE & INNOVATION 01.18.2023

Amgen’s Highest Honor Awarded to Peter Kufer for BiTE® Technology
$link.Title
PATIENTS 01.10.2023

What You Need to Know About Biosimilar Medicines
$link.Title
LEADERSHIP 01.10.2023

At Amgen, It’s "Innovate or Die" Says Amgen CEO Bob Bradway in Interview with Morgan Stanley
$link.Title
PEOPLE & CULTURE 01.05.2023

New Year, New You: Healthier Habits for 2023
$link.Title
PEOPLE & CULTURE 12.21.2022

Pioneering Epidemiologist to Retire and Data Reveals Hers was a Great Career at Amgen
$link.Title
RESPONSIBILITY 12.20.2022

10 Ways Amgen Supported Patients and Communities in 2022
$link.Title
RESPONSIBILITY 12.19.2022

Unwrap the Gift of Science with Amgen Leaders
PRESS RELEASE 12.12.2022

Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc
KRAS G12C

Visit Our KRAS G12C Information Center
MORE STORIES

Our Latest Press Releases

PRESS RELEASE white-right-arrow

PRESS RELEASE white-right-arrow

PRESS RELEASE white-right-arrow

PRESS RELEASE white-right-arrow

PRESS RELEASE white-right-arrow

More News


Global hotline for Ukrainian refugee patients participating in an Amgen clinical trial.
Click here for more information.

Our Story

Watch VideoLearn more

Our Science

Amgen is a pioneer in the science of using living cells to make biologic medicines.

Our Products

Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options.

Our Responsibility

Making a positive difference in the world is at the heart of what we do at Amgen—and it goes beyond making vital medicines.
Social Justice and Health Equity
View All
$name
12.03.2020
Amgen Foundation Announces Recipients of $5.25M to Support Social Justice and Equal Opportunity
$name
12.10.2020
Amgen Joins Coalition to Hire One Million Black Americans Over 10 Years
$name
05.31.2020
CEO Bob Bradway Shares Perspective on Death of George Floyd
$name
06.30.2020
Amgen Foundation Announces $7.5M to Support Racial Justice and Equal Opportunity
$name
10.05.2020
Coming Together to Advance Healthcare Equity
$name
11.17.2020
A Conversation on Social Justice: Amgen’s CEO and Echoing Green’s President

Amgen Investors

Amgen is a pioneer in the science of using living cells to making biologic medicines, leading and guiding the biotech industry.

Careers With Amgen

Encounter opportunities both new and undiscovered, as we embrace leading-edge technologies, invest in our talents, and maximize our potential.